Results 201 to 210 of about 303,574 (253)

SnRNA‐seq reveals cellular heterogeneity and proliferation mechanisms in limb venous malformations

Animal Models and Experimental Medicine, EarlyView.
To dissect the cellular heterogeneity and invasive mechanisms of limb venous malformations (VMs), this study first obtained tissue samples from four patients with VMs and four normal controls (NC). Single‐nucleus suspension was prepared, followed by transcriptome library construction and sequencing. After pretreatment, quality control, standardization,
Junjie Lin, Tingting Liu, Bin Fang, Xiaojuan Feng, Wenting Jiao, Changkuan Chen, Yaqing Ding, Gaozan Zhu, Wenqiu Wang, Wenbo Liu, Yuanqi Li, Shoufu Hou, Jianshe Wei, Junbo Qiao   +13 more
wiley   +1 more source

The liver‐brain axis: A multidimensional regulatory network implicated in Alzheimer's disease pathogenesis and clinical implications

Animal Models and Experimental Medicine, EarlyView.
Schematic diagram of the core pathways of the liver‐brain axis in regulating AD. The liver regulates cerebral Aβ deposition, tau phosphorylation, and neuroinflammation through pathways such as metabolic detoxification (urea cycle, ketone body metabolism, glutathione antioxidant system), molecular secretion (APOE, CRP, FGF21, IGF‐1), and Aβ clearance ...
Ning Zhang, Wei Chen, Meng Wang
wiley   +1 more source

The ErbB-tyrosine kinase inhibitor, neratinib, has anti-inflammatory effects in multimorbidity by increasing macrophage efferocytosis via the upregulation of MerTK. [PDF]

J Inflamm (Lond)
Bowden KA, Wright C, Clark S, Correa TF, Johnston SA, Marriott HM, Francis SE, Prince LR.   +7 more
europepmc   +1 more source

Adjuvant epidermal growth factor receptor tyrosine kinase inhibitor in resected stage N2 non-small cell lung cancer harboring <i>EGFR</i> mutation. [PDF]

Transl Lung Cancer Res
Xue Y, Wu Q, Li W, Xu F, Li Y, Zhou Q.
europepmc   +1 more source

Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997-2026). [PDF]

Chin Med J (Engl)
Xie Z, Chen X, Gao R, Yang M, Han X, Sun Y, Shi Y.   +6 more
europepmc   +1 more source

Jiedu Xiaozhen Granules for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Mediated Skin Toxicity: Protocol for a Randomized Controlled Trial. [PDF]

JMIR Res Protoc
Hao S, Li X, Hao S, Zhang X, Qi X, Jin G, Shen F, Liu L.   +7 more
europepmc   +1 more source

Evaluation of Cardiotoxicity in Lymphoproliferative Patients Treated With Anthracycline and Bruton's Tyrosine Kinase Inhibitor-Based Regimens. [PDF]

Cureus
Bonsu A.
europepmc   +1 more source

Novel Resistance Mechanisms to Second-Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC. [PDF]

Genes Chromosomes Cancer
Lin F, Zhao M, Wu Q, Wu W, Wu X, Ma Y, Yin JC, Yang M, Gao M.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tyrosine Kinase Inhibitors

Current Cancer Drug Targets, 2010
Over the last ten years, several new and therapeutically relevant cancer drugs targeting tyrosine kinases signaling pathways have been developed. Tyrosine kinase inhibitors (TKIs) are a pharmaceutical class of small molecules, orally available, well-tolerated, worldwide approved drugs for the treatment of several neoplasms, including lung, breast ...
NATOLI, Clara, Perrucci Bruno, Perrotti Francesca, Falchi Lorenzo, IACOBELLI, Stefano, Consorzio Interuniversitario Nazionale per Bio Oncologia   +5 more
openaire   +3 more sources